abstract: The 10th report of the European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium is presented, documenting cycles collected for the calendar year 2007 and follow-up of the pregnancies and babies born until October 2008 which resulted from these cycles. Since the beginning of the data collections there has been a steady increase in the number of cycles, pregnancies and babies reported annually. For data collection X, 57 centres participated, reporting on 5887 cycles to oocyte retrieval (OR), along with details of the follow-up on 1516 pregnancies and 1206 babies born. A total of 729 OR were reported for chromosomal abnormalities, 110 OR for sexing for X-linked diseases, 1203 OR for monogenic diseases, 3753 OR for preimplantation genetic screening and 92 OR for social sexing. Data X is compared with the cumulative data for data collections I -IX.
Introduction
The European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium was established in 1997. Since 1999, nine data collections of PGD for autosomal and sex-linked monogenic diseases and chromosome abnormalities, preimplantation genetic screening (PGS) and social sex selection have been published (ESHRE PGD Consortium Steering Committee, 1999 Sermon et al., 2005; Harper et al., 2006; 2008a,b; Sermon et al., 2007; Goossens et al. 2008 Goossens et al. , 2009 ). This report summarizes data X collected for the calendar year 2007 and the subsequent pregnancies. As it was reported for the first time in data VIII, data X also includes the delivery rate for each indication.
Materials and Methods
Data were collected using a FileMaker Pro 5, 6 or 8 database, consisting of files for cycle, pregnancy and baby records. OR, oocyte retrieval; AT, acid Tyrode's; COC, cumulus-oocyte complexes; SS, social sexing; PGS, preimplantation genetic screening; FISH, fluorescence in situ hybridization; ET, embryo transfer; ART, assisted reproduction technology; PB, polar body. PGD column includes PGD for chromosome abnormalities, sexing for X-linked disease and PGD for monogenic disorders.
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Includes two cycles with PGD on frozen embryos only. These cycles were not counted in the cycles with OR. AT drilling  273  207  491  568  108  117  1764   Laser drilling  283  159  348  345  121  86  1342   Mechanical  18  10  34  39  37  30  168   Biopsy method   PB biopsy  2  7  0  12  1  1  23   Cleavage aspiration  538  346  825  876  258  219  3062   Cleavage extrusion  32  23  37  50  4  13  159   Cleavage flow displacement  2  0  2  4  3  0  11   Blastocyst  0  0  9  10  0  0  19   Embryology   COC's  8836  5625  13 649  14 703  3714  3245  49 772   Inseminated  7385  4742  11 584  12 847  3036  2822  42 416   Fertilized  5022  3504  8270  9540  2133  2065  30 534   Biopsied  3502  2675  6364  7437  1489  1654  23 121   Successfully biopsied  3451  2646  6277  7339  1471  1634  22 818   Diagnosed  3113  2442  5836  6854  1355  1521  21 121   Transferable  1180  712  1150  1328  607  470  5447   Transferred  798  531  935  1087  414  329  4094   Frozen  144  65  53  73  61  49  445   Clinical outcome   Cycles to ET  447  288  542  609  214  181  2281   hCG positive  156  97  167  182  69  47  718 Table SIIc lists the abnormal karyotypes carried by the patients undergoing PGD, Supplementary Table SIIIc lists the X-linked diseases for  which sexing was carried out, Supplementary Table SIVc lists the  monogenic diseases for which PGD was carried out, Supplementary  Tables SVIIIa (data I -IX) and SVIIIb (data X) list the complications  of pregnancy and Supplementary Tables SXIIa (data I -IX) and SXIIb (data X) list the congenital malformations and the neonatal complications. An overview of all cycles collected previously in data collections I -IX can be found in Table Ia , while an overview of the current data collection can be found in Table Ib. For all indications for PGD/PGS (data I -IX and X), ICSI was the most often used method of fertilization and cleavage stage aspiration was the most commonly used method of biopsy. Overall zona pellucida drilling was more commonly performed using a laser. Tables IIa and IIb summarize the 3524 and 729 cycles to OR collected for data collection I-IX and X, respectively. As for previous years, data X showed that PGD for reciprocal translocations was performed more often than for Robertsonian translocations or other types of chromosome abnormalities. For data X 9045 oocytes were collected, 69% (5325/ 7727) fertilized, 74% (3947/5325) embryos were biopsied and 99% (3902/3947) embryos were successfully biopsied. Of the embryos successfully biopsied 94% (3652/3902) gave a diagnostic result, of which only 26% (938/3652) were transferable. From 729 OR procedures only 62% (450/729) resulted in an embryo transfer procedure. This is in agreement with previous data showing that a high level of chromosomally abnormal embryos is found in these patients. A positive hCG was obtained in 184 cycles, with a positive heart beat in 152 cycles [21% per OR (152/729) and 34% per embryo transfer (152/450)]. This gave an implantation rate of 26% (176/681). Finally, the delivery rate was 16% per OR (120/729) and 27% per embryo transfer (120/450). There were 18/138 miscarriages (13% per clinical pregnancy) and 9% (14/152) pregnancies were lost to follow-up. Tables IIIa and IIIb summarize the 1057 and 110 cycles to OR collected for data collection I -IX and X, respectively. This year, again, fluorescence in situ hybridization (FISH) was the only method used for sexing cycles. For data X, 1485 oocytes were collected, 70% (866/1238) fertilized, 79% (685/866) embryos were biopsied and 99% (681/685) were successfully biopsied. Of the embryos successfully biopsied, 94% (638/681) gave a diagnostic result, of which only 37% (236/638) were transferable (female). From 110 OR procedures only 78% (86/110) resulted in an embryo transfer procedure. A positive hCG was obtained in 25 cycles, with a positive heart beat in 22 cycles [20% per OR (22/110) Includes two cycles performed also with FISH for a Roberstonian translocation.
PGD cycles for chromosomal abnormalities

PGD cycles for sexing for X-linked diseases
3
Includes three cycles for SMA and PGS, and 5 cycles performed also for retinitis pigmentosa. Includes one cycle also for DMD.
5
Includes one cycle for BMD and PGS.
6
Includes three cycles for FRAX A testing and PGS.
7
Includes one cycle for Haem A and PGS.
8
Includes one cycle for Tuberous Sclerosis and PGS + 3 cycles using FISH for a microdeletion.
9
Two cycles were on frozen-thawed embryos only so they were not counted as cycles with an OR, but were counted as cycles going to PGD. (366/1660). These pregnancy rates were notably higher than in the previous data collections. Finally, the delivery rate was 21% per OR (253/1203) and 27% per embryo transfer (253/952). There were 37/290 miscarriages (13% per clinical pregnancy) and 3% (8/298) clinical pregnancies were lost to follow-up.
Overall, the number of PGD cycles performed for monogenic disorders between January and December 2007 further increased compared with data collection IX. This increase is primarily a result of a marked increase in the cycles for b-thalassemia and/or sickle cell syndromes (with HLA typing) (245 cycles in data X versus 110 cycles in data IX) and an increase in cycles for less frequent monogenic disorders (column 'others' in Table IVb) . Overall, there were no marked changes with respect to the progress and outcome of cycles, including the embryology, rates of diagnosis and clinical outcome, such as clinical pregnancy and embryo implantation rates (Goossens et al., 2009 ). Tables Va and Vb summarize In four cycles there was a second indication: in one CF was combined with HD, in two CF was combined with Haem (once via PCR and one via sexing), in a fourth CF was combined with PGS.
Preimplantation genetic screening
3
One cycle was also carried out for Marfan. 4 In three cycles HLA typing was combined with PGS.
5
There were five cycles with a double indication: one cycle for PGS, two cycles for Marfan and two cycles for Antley-Bixler. 6 2/17 cycles were performed for an X-linked form of CMT. In one cycle PCR for FRAXA was combined with FISH for X-linked mental retardation (sexing). These data were not extracted from I to IV.
2
These data were not extracted from I to III.
3
These data were not extracted from data I -VIII. 4 'Others' contains also cycles with multiple indications and previous abnormal (prev abn) pregnancies (data I -VIII). From 3753 cycles, 387 involved the biopsy of only one embryo and 555 involved the biopsy of two embryos. As stated in data VII (Harper et al., 2008a,b) , in the majority of cases these embryos should be replaced without biopsy.
There was only one cycle where PCR and FISH was used, in all other 3752 cycles to OR FISH was used.
In Table Vb , the column 'others' contains various indications such as mosaic embryos and single or double embryo transfer, as well as cycles with multiple indications.
The PGD Consortium recently published a position statement on the use of PGS (Harper et al., 2010a) . All RCTs for PGS using FISH and mainly cleavage-stage biopsy show no improvements in success rates. The Consortium recommendation was that the use of arrays on either polar bodies or trophectoderm biopsies should be validated and appropriate RCTs performed. The ESHRE PGS Task Force has conducted a pilot into the feasibility of using arrays for polar body biopsy (Geraedts et al., 2010) and is in the process of setting up an RCT.
PGD cycles for social sexing
Tables VIa and VIb summarize the 579 and 92 cycles to OR collected for data collection I -IX and X, respectively. For data X, 1377 oocytes were collected, 74% (866/1175) fertilized, 81% (703/866) embryos were biopsied and 98% (692/703) were successfully biopsied. Of the embryos successfully biopsied 82% (568/692) gave a diagnostic result, of which only 38% (213/568) were transferable (of the desired sex). From 92 OR procedures only 79% (73/92) resulted in an embryo transfer procedure. A positive hCG was obtained in 36 cycles, with a positive heart beat in 23 cycles [25% per OR (23/92 and 32% per embryo transfer (23/73)]. This gave an implantation rate of 23% (31/133). These pregnancy rates were similar to the previous data collections. Finally, the delivery rate was 20% per OR (18/ 92) and 25% per embryo transfer (18/73). There were 4/22 miscarriages (18% per clinical pregnancy) and 4% (1/23) was lost to follow-up.
Pregnancies and babies
Tables VIIa, VIIb, IXa -XIb, and Supplementary Tables SVIIIa, SVIIIb, SXIIa, SXIIb summarize the pregnancy and baby data. Data X was comparable to previous data collections. Data X included 1516 clinical pregnancies which resulted in 1609 fetal sacs (Table VIIb) TOP, termination of pregnancy. Two TOPs for ancephalocoele, one TOP for social reasons, one TOP of twin with misdiagnosis for CMT disease 1a, one TOP for 47,XY+13, one TOP for encephelocele and one TOP for 47,XY+21.
5
One heterotrophic gestation continued as singleton after reduction of extra-uterine gestation at 6 weeks.
6
One triplet: fetal reduction, followed by amniocentesis and loss of remaining twin at 16 weeks (1 fetal sac counted in reduction, 2 in miscarriage, 1 s trimester pregnancy loss after miscarriage counted).
7
TOP after misdiagnosis: one misdiagnosis for sexing, FISH, female fetus, indication SS; one misdiagnosis for b-Thal, PCR; one misdiagnosis for MD, PCR, one misdiagnosis after PGS, karyotype 45,X; one misdiagnosis for a reciprocal translocation 46,XY,der(15)t(13;15)(q25.1;q26.3). TOP after ultrasound (four): enlarged lateral ventricle, two singletons with cardiopathy, one singleton with tetralogy of Fallot. TOP after amniocentesis, not related to the PGD: trisomy 18, indication for PGD parent carrier of reciprocal translocation not involving chromosome 18; one polymalformation; one cystic hygroma, failed karyotype; one Turner mosaic, one spina bifida, one trisomy 21, one mosaic 46,XY/47,XY+18 (misdiagnosis), one Hemivertebrae, hypoplastic cerebellum, hydrocephaly (46,XX), one abnormal chromosome 15, one polycystic kidney.
8
One misdiagnosis for sexing, PCR, indication Duchenne, twin pregnancy, selective termination of male fetus. Cycle done in 1996, Y-specific amplification only.
9
One misdiagnosis (47,XXX after PGS for RIF) lost to FU.
ESHRE PGD consortium data collection X pregnancy with a positive heartbeat, follow-up data on 1271 pregnancies were reported. Of the 977 pregnancies reported to have ended with a delivery (total number of babies: 1206), neonatal data on 1206 babies were submitted. The delivery rates per indication are reported in Tables IIb, IIIb , IVb, Vb and VIb. Fifty per cent of the deliveries were by Caesarean section (489/977) ( Table IXb) . In 132 cases the method of delivery was not known.
Confirmation of the diagnosis was performed prenatally (441/1609) and/or postnatally (401/1609) ( Table Xb) . Supplementary Table SXIIb shows the abnormalities found during or after the pregnancy. Several abnormalities were found that were not related to the PGD.
This report again confirms that pregnancies and babies born after PGD are very similar to the pregnancies obtained and babies born after ICSI treatment (Bonduelle et al., 2002) . In our series, the number of multiple pregnancies remains high (293/1291, 23%) . This means 37% (448/1206) of the babies born are part of a multiplet at birth.
Misdiagnoses
Table XIIIa summarizes the misdiagnoses reported for data I-IX. For data X, no misdiagnoses have been reported. The Consortium has published a paper on the possible causes of misdiagnosis in PGD (Wilton et al., 2009) Misdiagnosis after gender selection for XL retinitis pigmentosa: male.
10
Two children had unknown check and karyotype. Figure 1 shows the pregnancy rate for each centre for data X. The average pregnancy rate is 21.73%. Success rate tends to be higher and more homogenous in the most active centres (performing more than 100 OR per year). Centres carrying out lower numbers of cycles may have lower rates owing to less experience. The findings, however, indicate that some of the most active centres fall below the average 22% pregnancy rate and even have pregnancy rates lower than some of the centres performing few cycles. A more detailed statistical analysis comparing success rates according to various factors (indication, women age at OR, etc.) should be performed to confirm these differences.
Success of individual centres
Discussion
This 10th report of the ESHRE PGD Consortium demonstrates, as in previous years, the continuing increase in the number of PGD cycles, with subsequent pregnancies and babies. Consortium; full membership for centres who submit annual data and associate membership for centres who cannot submit data (including new clinics, IVF units who work with a diagnostic laboratory that is a member of the Consortium). Associate centres performing PGD must send in summary data. For data X, only six associate centres sent in summary data and so these data were not included in this report. Most associate centres are satellite PGD centres that work with many IVF centres and they have reported that they cannot obtain information about the IVF cycles. Therefore, we have amended the information we will collect from associate centres to just include data on the diagnosis. As always, the centres who submit data have access to the raw data while the associate centres are allowed to participate in the annual Consortium meetings and they are sent the quarterly Consortium newsletter.
Besides data collection, the Consortium is involved with a number of activities through the working groups. Currently there are five working groups: accreditation, misdiagnosis auditing and monitoring, guidelines, database and molecular methods. The accreditation working group has organized two quality management meetings and has two more scheduled: 2011 (Athens) and 2012 (Istanbul) in collaboration with EuroGentest. The group has also written a paper on the accreditation process specifically relating to PGD and ISO15189 (Harper et al., 2010b) . This group annually collects data on the number of centres accredited. In many countries it is now becoming mandatory for all diagnostic laboratories to be accredited and the Consortium supports this as accreditation ensures quality of treatment. The FISH and PCR external quality assessment schemes (EQA) continue to operate annually and it is hoped that an array EQA will be set up in the near future. The misdiagnosis auditing and monitoring group are conducting two studies to examine the follow-up of embryos after PGD; one for PCR and one for FISH diagnoses. It is key that all centres utilize their untransferred embryos to validate and audit the methods that they are using and to calculate the efficacy of their techniques. The misdiagnosis working group wrote a paper on the causes of misdiagnosis (Wilton et al., 2009) . The guidelines working group has almost finished its task. Four new specific guidelines have been written: organization of a PGD/PGS Centre, Amplification-based PGD, FISH-based PGD and Embryo Biopsy and Embryology. Three of the four documents are available on the ESHRE website for discussion and suggestion, whereas the Embryo Biopsy Guideline is in the final stages of preparation and will be available online soon. All four guideline documents should be published before the end of 2010. The database working group has been refining the data collection and developing a database for the frozen embryo data. This will become more important as centres move to arrays and vitrification for their diagnoses (Harper and Harton, 2010) . The molecular methods working group has set up a database of primers which is only open to full Consortium members. It is essential that all primer sets are validated in individual laboratories before clinical use.
From the ten data collections, the Consortium now has detailed data on 27 630 cycles and 4047 babies born after PGD/PGS.
The large amount of detailed information the Consortium has collected is unique and studies are underway to analyse many aspects of the data in more depth. ogy/IVF Unit; AVA-Clinic; France: SIHCUS-CMCO, Unité de Indicates the number of newborns for whom information is available out of the total number of newborns.
2
Good is defined ≥7, poor is defined ,7. 
